Westhampton Capital LLC Lowers Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Westhampton Capital LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,187 shares of the medical research company’s stock after selling 30 shares during the period. Westhampton Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,271,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TMO. Northwest Financial Advisors purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. True Wealth Design LLC increased its stake in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares in the last quarter. Pineridge Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $39,000. Cape Investment Advisory Inc. grew its stake in shares of Thermo Fisher Scientific by 52.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after buying an additional 26 shares during the last quarter. Finally, Raleigh Capital Management Inc. raised its stake in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after buying an additional 27 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock valued at $12,532,780 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $6.15 during mid-day trading on Tuesday, hitting $535.57. The company had a trading volume of 406,451 shares, compared to its average volume of 1,541,971. The company has a market capitalization of $204.44 billion, a P/E ratio of 34.53, a P/E/G ratio of 2.58 and a beta of 0.77. The stock’s 50 day moving average price is $574.84 and its 200-day moving average price is $563.36. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. HSBC boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Jefferies Financial Group reissued a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $606.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.